Project 170526
Metabolic Regulation of Toll-like Receptor Agonist Therapy in Leukemia
Metabolic Regulation of Toll-like Receptor Agonist Therapy in Leukemia
Project Information
| Study Type: | Other Mechanistic_Study |
| Therapeutic Area: | Oncology |
| Research Theme: | Biomedical |
| Disease Area: | Chronic Lymphocytic Leukemia |
| Data Type: | Canadian |
Institution & Funding
| Principal Investigator(s): | Spaner, David E |
| Institution: | Sunnybrook Research Institute (Toronto, Ontario) |
| CIHR Institute: | Cancer Research |
| Program: | |
| Peer Review Committee: | Cancer Biology & Therapeutics |
| Competition Year: | 2008 |
| Term: | 3 yrs 0 mth |
Abstract Summary
Chemotherapy does not cure most cancers. However, the results with chemotherapy may be improved with treatments that increase the ability of the immune system to kill cancer cells (or immunotherapy). We have found that a new agent (called S28690), which activates a receptor on immune cells, called Toll-like receptor 7 (or TLR7), makes tumor cells more susceptible to both chemotherapy in the test tube but is not as effective in patients. The proposed research will determine how to make S28690 more effective in patients with Chronic Lymphocytic Leukemia, which is a tumor of the blood system. If these studies are successful,a new treatment for leukemia, and possibly other cancers, will become available.
Research Characteristics
This project includes the following research characteristics:
Study Justification
"determine how to make S28690 more effective in patients with Chronic Lymphocytic Leukemia"
Novelty Statement
"found that a new agent (called S28690), which activates a receptor on immune cells, called Toll-like receptor 7 (or TLR7), makes tumor cells more susceptible to both chemotherapy"
Methodology Innovation
N/A